“We can close the NCD access gap by ensuring that innovative new tools and existing technologies are within reach for people who need them, regardless of where they live” -Steve Davis, PATH President & CEO
New York, New York (PRWEB)
September 18, 2017
A multisectoral partnership today launched a first-of-its-kind global coalition dedicated to increasing access to essential medicines and health products to prevent and treat noncommunicable diseases (NCDs) and conditions, including diabetes, hypertension, and cardiovascular disease.
The new Coalition for Access to NCD Medicines & Products brings together governments, the private sector, philanthropic and academic institutions, and nongovernmental organizations to tackle barriers countries face in procuring, supplying, and distributing essential medicines and technologies and ensuring they are used effectively. PATH will serve as the coalition secretariat.
The coalition will partner with countries to help them achieve the World Health Organization target of 80 percent availability of affordable technologies and essential medicines, including generics, required to treat NCDs in both public and private facilities.
The launch event, alongside the United Nations General Assembly in New York, features an interactive panel of global health leaders and influencers from across sectors sharing their perspectives on the opportunities ahead to reduce the toll of NCDs.
Panel speakers include Peter Singer, CEO of Grand Challenges Canada; Sir George Alleyne, director emeritus, Pan American Health Organization; Khawar Mann, partner with the Abraaj Group; Rebecca Martin, director of the Center for Global Health at the US Centers for Disease Control and Prevention; Jean Claude Mbanya, professor of medicine and endocrinology at the University of Yaoundé in Cameroon; and Sania Nishtar, founder and president of Heartfile.
“Medicines and technologies for chronic diseases are less available and less affordable for people in low-resource countries,” said Steve Davis, PATH president and CEO. “That equity gap leaves the most vulnerable people at greater risk for complications and death from NCDs. We can close the gap by ensuring that innovative new tools and existing technologies are within reach for people who need them, regardless of where they…